Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4550811
Max Phase: Preclinical
Molecular Formula: C44H67N11O12S2
Molecular Weight: 1006.22
Molecule Type: Unknown
Associated Items:
ID: ALA4550811
Max Phase: Preclinical
Molecular Formula: C44H67N11O12S2
Molecular Weight: 1006.22
Molecule Type: Unknown
Associated Items:
Canonical SMILES: CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)CCCSC[C@@H](C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CSCC(N)=O)NC1=O
Standard InChI: InChI=1S/C44H67N11O12S2/c1-5-24(4)37-43(66)52-30(20-69-22-35(47)59)41(64)50-29(18-33(45)57)39(62)53-31(21-68-15-7-9-36(60)49-28(40(63)54-37)17-25-10-12-26(56)13-11-25)44(67)55-14-6-8-32(55)42(65)51-27(16-23(2)3)38(61)48-19-34(46)58/h10-13,23-24,27-32,37,56H,5-9,14-22H2,1-4H3,(H2,45,57)(H2,46,58)(H2,47,59)(H,48,61)(H,49,60)(H,50,64)(H,51,65)(H,52,66)(H,53,62)(H,54,63)/t24-,27-,28-,29-,30-,31-,32-,37-/m0/s1
Standard InChI Key: UPMFUNZRDWWIPZ-VNHOCEMUSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 1006.22 | Molecular Weight (Monoisotopic): 1005.4412 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Pflimlin E, Zhou Z, Amso Z, Fu Q, Lee C, Muppiddi A, Joseph SB, Nguyen-Tran V, Shen W.. (2020) Engineering a Potent, Long-Acting, and Periphery-Restricted Oxytocin Receptor Agonist with Anorexigenic and Body Weight Reducing Effects., 63 (1): [PMID:31850759] [10.1021/acs.jmedchem.9b01862] |
Source(1):